Stratagen Quantitative Prostate MRI Platform Pilot Study
Intervencionista
Fase no especificada
Urology Clinic at Sawgrass
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.
* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters?
Participants will:
- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Categoría de tratamiento
Dispositivo
Erforderliche Mutationen
Ninguna
Ensayo iniciado
2025-09-24
Última actualización por el patrocinador
2025-10-21
Finalización estimada
2025-11-30
Elegibilidad
Criterios de inclusión
* Subject has a prostate that would be considered for biopsy
* Age 40-90 years
* PSA ≥ 2.5
* Subject has been informed of the nature of the study and has provided written informed consent
Criterios de exclusión
* Contraindication for MRI
* Prostate biopsy within the previous 12 weeks
* Implant in the pelvis that may cause artifact on MRI (e.g. hip replacement)
* History of prostatectomy or other local prostate cancer therapy (e.g., cryotherapy or brachytherapy), or previous pelvic irradiation
* Currently enrolled in another investigational drug or device study that clinically interferes with this study
* Unable to comply with the study requirements or follow up schedule
* Any condition the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the subject
¿Cree usted que este ensayo clínico se muestra por error?
Detalles del diseño
AsignaciónN/A
Modelo de intervenciónSingle Group Assignment
EnmascaramientoNone (Open Label)
Número a inscribir45
Brazos e Intervenciones
Brazos
Intervenciones
Tipo: Experimental
Descripción:
Intervenciones:
MRI
Medidas de resultado
Medidas de resultado primarias
Safety: no SAEs attributable to the Stratagen Quantitative Prostate MRI Platform, as determined by participating Investigator according to CTCAE guidelinesBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
All serious adverse events attributable to the Stratagen Quantitative Prostate MRI Platform will be reported.
• Feasibility: collection of the data necessary to produce measurable quantitative T1 and T2 relaxation times (milliseconds) maps (images) for at least 80% of pixels fully contained within the prostate for at least 80% of subjectsBeginning of MRI Scan to end of MRI scan (MRI Scan Visit, Day 0)
Medidas de resultado secundarias
Ninguno
¿Interesado en participar?
Obtenga más información sobre este ensayo y si puede ser elegible para participar.
Guardar ensayo
Compartir ensayo por correo electrónico
Descargar ensayo
¿Cree usted que este ensayo clínico se muestra por error?
Reportar ensayo
Descargar ensayo
Sitios del ensayo
Este estudio tiene 1 sitio de ensayo
Urology Clinic at Sawgrass Rochester, New York, US